{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:42:54Z","timestamp":1791934974301,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41440-024-01592-z","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T10:02:37Z","timestamp":1709546557000},"page":"1479-1489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systolic blood pressure visit-to-visit variability and outcomes in Asian patients with atrial fibrillation"],"prefix":"10.1038","volume":"47","author":[{"given":"Ply","family":"Chichareon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komsing","family":"Methavigul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungroj","family":"Krittayaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"1592_CR1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.117.08934","volume":"70","author":"MS Dzeshka","year":"2017","unstructured":"Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. Hypertension. 2017;70:854\u201361.","journal-title":"Hypertension"},{"key":"1592_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/00015385.2021.1882111","volume":"77","author":"RE Harskamp","year":"2022","unstructured":"Harskamp RE, Lucassen WAM, Lopes RD, Himmelreich JCL, Parati G, Weert H. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol. 2022;77:191\u20135.","journal-title":"Acta Cardiol"},{"key":"1592_CR3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa003417","volume":"345","author":"RS Vasan","year":"2001","unstructured":"Vasan RS, Larson MG, Leip EP, Evans JC, O\u2019Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl J Med. 2001;345:1291\u20137.","journal-title":"N. Engl J Med"},{"key":"1592_CR4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2018.07.008","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1278\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"1592_CR5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","volume":"72","author":"D Kim","year":"2018","unstructured":"Kim D, Yang P-S, Kim T-H, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:1233\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"1592_CR6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41569-022-00690-0","volume":"19","author":"AE Schutte","year":"2022","unstructured":"Schutte AE, Kollias A, Stergiou GS. Blood pressure and its variability: classic and novel measurement techniques. Nat Rev Cardiol. 2022;19:643\u201354.","journal-title":"Nat Rev Cardiol"},{"key":"1592_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.119.13708","volume":"75","author":"SR Lee","year":"2020","unstructured":"Lee SR, Choi YJ, Choi EK, Han KD, Lee E, Cha MJ, et al. Blood pressure variability and incidence of new-onset atrial fibrillation: a nationwide population-based study. Hypertension. 2020;75:309\u201315.","journal-title":"Hypertension"},{"key":"1592_CR8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1161\/HYPERTENSIONAHA.117.10106","volume":"70","author":"M Proietti","year":"2017","unstructured":"Proietti M, Romiti GF, Olshansky B, Lip GYH. Systolic blood pressure visit-to-visit variability and major adverse outcomes in atrial fibrillation: The AFFIRM Study (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). Hypertension. 2017;70:949\u201358.","journal-title":"Hypertension"},{"key":"1592_CR9","first-page":"395","volume":"2","author":"C-E Chiang","year":"2022","unstructured":"Chiang C-E, Chao T-F, Choi E-K, Lim TW, Krittayaphong R, Li M. et al. Stroke Prevention in Atrial Fibrillation. JACC: Asia. 2022;2:395\u2013411.","journal-title":"JACC: Asia"},{"key":"1592_CR10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","volume":"122","author":"DA Gorog","year":"2022","unstructured":"Gorog DA, Gue YX, Chao T-F, Fauchier L, Ferreiro JL, Huber K, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost. 2022;122:1625\u201352.","journal-title":"Thromb Haemost"},{"key":"1592_CR11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","volume":"121","author":"HK Kim","year":"2021","unstructured":"Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park SJ, Kim MH, et al. The East Asian Paradox: An updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost. 2021;121:422\u201332.","journal-title":"Thromb Haemost"},{"key":"1592_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/HYPERTENSIONAHA.113.01426","volume":"62","author":"N Pagonas","year":"2013","unstructured":"Pagonas N, Schmidt S, Eysel J, Compton F, Hoffmann C, Seibert F, et al. Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension. 2013;62:579\u201384.","journal-title":"Hypertension"},{"key":"1592_CR13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"1592_CR14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236\u20139.","journal-title":"Thromb Haemost"},{"key":"1592_CR15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/eurheartj\/ehl504","volume":"28","author":"GYH Lip","year":"2007","unstructured":"Lip GYH, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752\u20139.","journal-title":"Eur Heart J"},{"key":"1592_CR16","doi-asserted-by":"crossref","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","volume":"4","author":"MP Rao","year":"2015","unstructured":"Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015;4:e002015.","journal-title":"J Am Heart Assoc"},{"key":"1592_CR17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.amjcard.2015.07.032","volume":"116","author":"R Nagarakanti","year":"2015","unstructured":"Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116:1204\u20139.","journal-title":"Am J Cardiol"},{"key":"1592_CR18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/eurheartj\/ehac245","volume":"43","author":"GYH Lip","year":"2022","unstructured":"Lip GYH, Lane DA, Lenarczyk R, Boriani G, Doehner W, Benjamin LA, et al. Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur Heart J. 2022;43:2442\u201360.","journal-title":"Eur Heart J"},{"key":"1592_CR19","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1093\/eurheartj\/suaa061","volume":"22","author":"EA Rosei","year":"2020","unstructured":"Rosei EA, Chiarini G, Rizzoni D. How important is blood pressure variability? Eur Heart J Suppl. 2020;22:E1\u2013e6.","journal-title":"Eur Heart J Suppl"},{"key":"1592_CR20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41440-020-0421-5","volume":"43","author":"G Parati","year":"2020","unstructured":"Parati G, Torlasco C, Pengo M, Bilo G, Ochoa JE. Blood pressure variability: its relevance for cardiovascular homeostasis and cardiovascular diseases. Hypertens Res. 2020;43:609\u201320.","journal-title":"Hypertens Res"},{"key":"1592_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/HYPERTENSIONAHA.115.06960","volume":"68","author":"IM Kronish","year":"2016","unstructured":"Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, et al. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure. Hypertension. 2016;68:39\u201345.","journal-title":"Hypertension"},{"key":"1592_CR22","doi-asserted-by":"crossref","first-page":"e018585","DOI":"10.1161\/JAHA.120.018585","volume":"10","author":"E Kodani","year":"2021","unstructured":"Kodani E, Inoue H, Atarashi H, Okumura K, Yamashita T, Otsuka T, et al. Impact of blood pressure visit\u2010to\u2010visit variability on adverse events in patients with nonvalvular atrial fibrillation: subanalysis of the J\u2010RHYTHM Registry. J Am Heart Assoc. 2021;10:e018585.","journal-title":"J Am Heart Assoc"},{"key":"1592_CR23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amepre.2022.03.007","volume":"63","author":"B Haring","year":"2022","unstructured":"Haring B, Hunt RP, Manson JE, LaMonte MJ, Klein L, Allison MA, et al. Blood pressure variability and heart failure hospitalization: results from the women\u2019s health initiative. Am J Preventive Med. 2022;63:410\u20138.","journal-title":"Am J Preventive Med"},{"key":"1592_CR24","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/HYPERTENSIONAHA.120.16209","volume":"76","author":"ME Ernst","year":"2020","unstructured":"Ernst ME, Chowdhury EK, Beilin LJ, Margolis KL, Nelson MR, Wolfe R, et al. Long-term blood pressure variability and risk of cardiovascular disease events among community-dwelling elderly. Hypertension. 2020;76:1945\u201352.","journal-title":"Hypertension"},{"key":"1592_CR25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dc19-2540","volume":"43","author":"DS Nuyujukian","year":"2020","unstructured":"Nuyujukian DS, Koska J, Bahn G, Reaven PD, Zhou JJ. Blood pressure variability and risk of heart failure in ACCORD and the VADT. Diabetes Care. 2020;43:1471\u20138.","journal-title":"Diabetes Care"},{"key":"1592_CR26","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/eurheartj\/ehx760","volume":"39","author":"MH Mehlum","year":"2018","unstructured":"Mehlum MH, Liest\u00f8l K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 2018;39:2243\u201351.","journal-title":"Eur Heart J"},{"key":"1592_CR27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/HYPERTENSIONAHA.120.16757","volume":"77","author":"F-F Wei","year":"2021","unstructured":"Wei F-F, Zhou Y, Thijs L, Xue R, Dong B, He X, et al. Visit-to-visit blood pressure variability and clinical outcomes in patients with heart failure with preserved ejection fraction. Hypertension. 2021;77:1549\u201358.","journal-title":"Hypertension"},{"key":"1592_CR28","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.108.821306","volume":"119","author":"E Anter","year":"2009","unstructured":"Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure. Circulation. 2009;119:2516\u201325.","journal-title":"Circulation"},{"key":"1592_CR29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","volume":"7","author":"MA Carlisle","year":"2019","unstructured":"Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019;7:447\u201356.","journal-title":"JACC Heart Fail"},{"key":"1592_CR30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/01.CIR.102.4.470","volume":"102","author":"BH Lorell","year":"2000","unstructured":"Lorell BH, Carabello BA. Left ventricular hypertrophy. Circulation. 2000;102:470\u20139.","journal-title":"Circulation"},{"key":"1592_CR31","volume":"26","author":"GC Oh","year":"2020","unstructured":"Oh GC, Cho H-J. Blood pressure and heart failure. Clin Hypertens. 2020;26:1.","journal-title":"Clin Hypertens"},{"key":"1592_CR32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/europace\/euaa253","volume":"23","author":"E Arbelo","year":"2021","unstructured":"Arbelo E, Aktaa S, Bollmann A, D\u2019Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace. 2021;23:494\u20135.","journal-title":"Europace"},{"key":"1592_CR33","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/jcm9061698","volume":"9","author":"R Krittayaphong","year":"2020","unstructured":"Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF Registry. J Clin Med. 2020;9:1698.","journal-title":"J Clin Med"},{"key":"1592_CR34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.11622\/smedj.2019143","volume":"61","author":"R Krittayaphong","year":"2020","unstructured":"Krittayaphong R, Winijkul A, Pirapatdit A, Chiewvit P, Komoltri C, Boonyapisit W, et al. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singap Med J. 2020;61:641\u20136.","journal-title":"Singap Med J"},{"key":"1592_CR35","doi-asserted-by":"crossref","unstructured":"Group JCSJW. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014;78:1997\u20132021.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"1592_CR36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","volume":"122","author":"TF Chao","year":"2022","unstructured":"Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost. 2022;122:20\u201347.","journal-title":"Thromb Haemost"},{"key":"1592_CR37","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.amjcard.2017.07.050","volume":"120","author":"T Liu","year":"2017","unstructured":"Liu T, Hui J, Hou YY, Zou Y, Jiang WP, Yang XJ, et al. Meta-analysis of efficacy and safety of low-intensity warfarin therapy for East Asian patients with nonvalvular atrial fibrillation. Am J Cardiol. 2017;120:1562\u20137.","journal-title":"Am J Cardiol"},{"key":"1592_CR38","first-page":"107602962311710","volume":"29","author":"JG Cho","year":"2023","unstructured":"Cho JG, Lee KH, Kim YR, Kim S, Gwak J, Cho E, et al. Standard-intensity versus low-intensity anticoagulation with warfarin in asian patients with atrial fibrillation: a multi-center, randomized controlled trial. Clin Appl Thromb Hemost. 2023;29:10760296231171081.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1592_CR39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14:627\u20138.","journal-title":"Nat Rev Cardiol"},{"key":"1592_CR40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42:373\u2013498.","journal-title":"Eur Heart J"},{"key":"1592_CR41","doi-asserted-by":"crossref","first-page":"e025322","DOI":"10.1136\/bmjopen-2018-025322","volume":"9","author":"HM Lim","year":"2019","unstructured":"Lim HM, Chia YC, Ching SM, Chinna K. Number of blood pressure measurements needed to estimate long-term visit-to-visit systolic blood pressure variability for predicting cardiovascular risk: a 10-year retrospective cohort study in a primary care clinic in Malaysia. BMJ Open. 2019;9:e025322.","journal-title":"BMJ Open"},{"key":"1592_CR42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4070\/kcj.2018.0190","volume":"48","author":"YG Li","year":"2018","unstructured":"Li YG, Lee SR, Choi EK, Lip GY. Stroke prevention in atrial fibrillation: focus on Asian patients. Korean Circ J. 2018;48:665\u201384.","journal-title":"Korean Circ J"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01592-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01592-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01592-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T23:04:36Z","timestamp":1717542276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01592-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01592-z","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PC reported a research grant from the National Research Council of Thailand, honorarium from AstraZeneca, Medtronic, Bayer, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, and Biotronik outside the submitted work. GYHL: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthem. No fees are received personally. GYHL is a co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation program under grant agreement No 899871. The remaining authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}